Eintrag weiter verarbeiten
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Blood, 97, 2001, 7, S. 2008-2015 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Sun, Xuemei Layton, Judith E. Elefanty, Andrew Lieschke, Graham J. Sun, Xuemei Layton, Judith E. Elefanty, Andrew Lieschke, Graham J. |
|---|---|
| author |
Sun, Xuemei Layton, Judith E. Elefanty, Andrew Lieschke, Graham J. |
| spellingShingle |
Sun, Xuemei Layton, Judith E. Elefanty, Andrew Lieschke, Graham J. Blood Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 Cell Biology Hematology Immunology Biochemistry |
| author_sort |
sun, xuemei |
| spelling |
Sun, Xuemei Layton, Judith E. Elefanty, Andrew Lieschke, Graham J. 1528-0020 0006-4971 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v97.7.2008 <jats:title>Abstract</jats:title><jats:p>STI571 (formerly CGP57148) and AG957 are small molecule inhibitors of the protein tyrosine kinase (PTK) p145abland its oncogenic derivative p210bcr-abl. AG490 is an inhibitor of the PTK Janus kinase 2 (JAK2). No direct comparison of these inhibitors has previously been reported, so this study compared their effects on factor-dependent FDC-P1, 32D, and MO7e cells and their p210bcr-abl-expressing factor-independent derivatives. STI571 was a more potent inhibitor of3H-thymidine incorporation in p210bcr-abl-expressing cells than was AG957, and it showed superior discrimination between inhibitory effects on parental cell lines and effects on their p210bcr-abl-expressing derivatives. Assays performed with and without growth factor demonstrated that STI571 but not AG957 reversed the p210bcr-abl-driven factor independence of cell lines. p210bcr-abl-expressing cells were less sensitive to AG490 than to AG957 or STI571. However, for p210bcr-abl-expressing clones from all 3 cell lines, synergistic inhibition was demonstrated between STI571 and concentrations of AG490 with no independent inhibitory effect. Inhibition of nucleic acid synthesis with AG957 treatment was associated with reduced cell numbers, reduced viability, and small pyknotic apoptotic cells. At concentrations of STI571 that reversed the p210bcr-abl factor-independent phenotype, STI571 treatment and growth factor deprivation together were sufficient to induce apoptosis. This study concludes that, for the cell lines studied, (1) STI571 is a more potent and more selective inhibitor of a p210bcr-abl-dependent phenotype than AG957; (2) AG490 synergizes with STI571 to enhance its inhibitory effect on p210bcr-abl-driven proliferation; and (3) the combination of p210bcr-abl-tyrosine kinase inhibition and growth factor signal withdrawal can be sufficient to induce apoptotic death of transformed cells.</jats:p> Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 Blood |
| doi_str_mv |
10.1182/blood.v97.7.2008 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52OTcuNy4yMDA4 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52OTcuNy4yMDA4 |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Hematology, 2001 |
| imprint_str_mv |
American Society of Hematology, 2001 |
| issn |
1528-0020 0006-4971 |
| issn_str_mv |
1528-0020 0006-4971 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
sun2001comparisonofeffectsofthetyrosinekinaseinhibitorsag957ag490andsti571onbcrablexpressingcellsdemonstratingsynergybetweenag490andsti571 |
| publishDateSort |
2001 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_unstemmed |
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_full |
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_fullStr |
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_full_unstemmed |
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_short |
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_sort |
comparison of effects of the tyrosine kinase inhibitors ag957, ag490, and sti571 on bcr-abl–expressing cells, demonstrating synergy between ag490 and sti571 |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood.v97.7.2008 |
| publishDate |
2001 |
| physical |
2008-2015 |
| description |
<jats:title>Abstract</jats:title><jats:p>STI571 (formerly CGP57148) and AG957 are small molecule inhibitors of the protein tyrosine kinase (PTK) p145abland its oncogenic derivative p210bcr-abl. AG490 is an inhibitor of the PTK Janus kinase 2 (JAK2). No direct comparison of these inhibitors has previously been reported, so this study compared their effects on factor-dependent FDC-P1, 32D, and MO7e cells and their p210bcr-abl-expressing factor-independent derivatives. STI571 was a more potent inhibitor of3H-thymidine incorporation in p210bcr-abl-expressing cells than was AG957, and it showed superior discrimination between inhibitory effects on parental cell lines and effects on their p210bcr-abl-expressing derivatives. Assays performed with and without growth factor demonstrated that STI571 but not AG957 reversed the p210bcr-abl-driven factor independence of cell lines. p210bcr-abl-expressing cells were less sensitive to AG490 than to AG957 or STI571. However, for p210bcr-abl-expressing clones from all 3 cell lines, synergistic inhibition was demonstrated between STI571 and concentrations of AG490 with no independent inhibitory effect. Inhibition of nucleic acid synthesis with AG957 treatment was associated with reduced cell numbers, reduced viability, and small pyknotic apoptotic cells. At concentrations of STI571 that reversed the p210bcr-abl factor-independent phenotype, STI571 treatment and growth factor deprivation together were sufficient to induce apoptosis. This study concludes that, for the cell lines studied, (1) STI571 is a more potent and more selective inhibitor of a p210bcr-abl-dependent phenotype than AG957; (2) AG490 synergizes with STI571 to enhance its inhibitory effect on p210bcr-abl-driven proliferation; and (3) the combination of p210bcr-abl-tyrosine kinase inhibition and growth factor signal withdrawal can be sufficient to induce apoptotic death of transformed cells.</jats:p> |
| container_issue |
7 |
| container_start_page |
2008 |
| container_title |
Blood |
| container_volume |
97 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348200782266371 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:07:13.984Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Comparison+of+effects+of+the+tyrosine+kinase+inhibitors+AG957%2C+AG490%2C+and+STI571+on+BCR-ABL%E2%80%93expressing+cells%2C+demonstrating+synergy+between+AG490+and+STI571&rft.date=2001-04-01&genre=article&issn=0006-4971&volume=97&issue=7&spage=2008&epage=2015&pages=2008-2015&jtitle=Blood&atitle=Comparison+of+effects+of+the+tyrosine+kinase+inhibitors+AG957%2C+AG490%2C+and+STI571+on+BCR-ABL%E2%80%93expressing+cells%2C+demonstrating+synergy+between+AG490+and+STI571&aulast=Lieschke&aufirst=Graham+J.&rft_id=info%3Adoi%2F10.1182%2Fblood.v97.7.2008&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348200782266371 |
| author | Sun, Xuemei, Layton, Judith E., Elefanty, Andrew, Lieschke, Graham J. |
| author_facet | Sun, Xuemei, Layton, Judith E., Elefanty, Andrew, Lieschke, Graham J., Sun, Xuemei, Layton, Judith E., Elefanty, Andrew, Lieschke, Graham J. |
| author_sort | sun, xuemei |
| container_issue | 7 |
| container_start_page | 2008 |
| container_title | Blood |
| container_volume | 97 |
| description | <jats:title>Abstract</jats:title><jats:p>STI571 (formerly CGP57148) and AG957 are small molecule inhibitors of the protein tyrosine kinase (PTK) p145abland its oncogenic derivative p210bcr-abl. AG490 is an inhibitor of the PTK Janus kinase 2 (JAK2). No direct comparison of these inhibitors has previously been reported, so this study compared their effects on factor-dependent FDC-P1, 32D, and MO7e cells and their p210bcr-abl-expressing factor-independent derivatives. STI571 was a more potent inhibitor of3H-thymidine incorporation in p210bcr-abl-expressing cells than was AG957, and it showed superior discrimination between inhibitory effects on parental cell lines and effects on their p210bcr-abl-expressing derivatives. Assays performed with and without growth factor demonstrated that STI571 but not AG957 reversed the p210bcr-abl-driven factor independence of cell lines. p210bcr-abl-expressing cells were less sensitive to AG490 than to AG957 or STI571. However, for p210bcr-abl-expressing clones from all 3 cell lines, synergistic inhibition was demonstrated between STI571 and concentrations of AG490 with no independent inhibitory effect. Inhibition of nucleic acid synthesis with AG957 treatment was associated with reduced cell numbers, reduced viability, and small pyknotic apoptotic cells. At concentrations of STI571 that reversed the p210bcr-abl factor-independent phenotype, STI571 treatment and growth factor deprivation together were sufficient to induce apoptosis. This study concludes that, for the cell lines studied, (1) STI571 is a more potent and more selective inhibitor of a p210bcr-abl-dependent phenotype than AG957; (2) AG490 synergizes with STI571 to enhance its inhibitory effect on p210bcr-abl-driven proliferation; and (3) the combination of p210bcr-abl-tyrosine kinase inhibition and growth factor signal withdrawal can be sufficient to induce apoptotic death of transformed cells.</jats:p> |
| doi_str_mv | 10.1182/blood.v97.7.2008 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52OTcuNy4yMDA4 |
| imprint | American Society of Hematology, 2001 |
| imprint_str_mv | American Society of Hematology, 2001 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1528-0020, 0006-4971 |
| issn_str_mv | 1528-0020, 0006-4971 |
| language | English |
| last_indexed | 2024-03-01T18:07:13.984Z |
| match_str | sun2001comparisonofeffectsofthetyrosinekinaseinhibitorsag957ag490andsti571onbcrablexpressingcellsdemonstratingsynergybetweenag490andsti571 |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 2008-2015 |
| publishDate | 2001 |
| publishDateSort | 2001 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Sun, Xuemei Layton, Judith E. Elefanty, Andrew Lieschke, Graham J. 1528-0020 0006-4971 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v97.7.2008 <jats:title>Abstract</jats:title><jats:p>STI571 (formerly CGP57148) and AG957 are small molecule inhibitors of the protein tyrosine kinase (PTK) p145abland its oncogenic derivative p210bcr-abl. AG490 is an inhibitor of the PTK Janus kinase 2 (JAK2). No direct comparison of these inhibitors has previously been reported, so this study compared their effects on factor-dependent FDC-P1, 32D, and MO7e cells and their p210bcr-abl-expressing factor-independent derivatives. STI571 was a more potent inhibitor of3H-thymidine incorporation in p210bcr-abl-expressing cells than was AG957, and it showed superior discrimination between inhibitory effects on parental cell lines and effects on their p210bcr-abl-expressing derivatives. Assays performed with and without growth factor demonstrated that STI571 but not AG957 reversed the p210bcr-abl-driven factor independence of cell lines. p210bcr-abl-expressing cells were less sensitive to AG490 than to AG957 or STI571. However, for p210bcr-abl-expressing clones from all 3 cell lines, synergistic inhibition was demonstrated between STI571 and concentrations of AG490 with no independent inhibitory effect. Inhibition of nucleic acid synthesis with AG957 treatment was associated with reduced cell numbers, reduced viability, and small pyknotic apoptotic cells. At concentrations of STI571 that reversed the p210bcr-abl factor-independent phenotype, STI571 treatment and growth factor deprivation together were sufficient to induce apoptosis. This study concludes that, for the cell lines studied, (1) STI571 is a more potent and more selective inhibitor of a p210bcr-abl-dependent phenotype than AG957; (2) AG490 synergizes with STI571 to enhance its inhibitory effect on p210bcr-abl-driven proliferation; and (3) the combination of p210bcr-abl-tyrosine kinase inhibition and growth factor signal withdrawal can be sufficient to induce apoptotic death of transformed cells.</jats:p> Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 Blood |
| spellingShingle | Sun, Xuemei, Layton, Judith E., Elefanty, Andrew, Lieschke, Graham J., Blood, Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_full | Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_fullStr | Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_full_unstemmed | Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_short | Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| title_sort | comparison of effects of the tyrosine kinase inhibitors ag957, ag490, and sti571 on bcr-abl–expressing cells, demonstrating synergy between ag490 and sti571 |
| title_unstemmed | Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571 |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood.v97.7.2008 |